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Inhibitors of axonal regeneration in myelin are believed to be major contributors to the lack of regeneration in
the adult CNS. Three of the four knownmyelin inhibitors, although very different structurally, interact with the
same receptor, NgR. However, the absence of NgR has no effect on inhibition of neurite outgrowth in culture,
and there is no improvement in CST regeneration in vivo. In a recent issue of Science, a second receptor for
these myelin inhibitors was described, PirB, a receptor first described in the immune system.Will PirB be the
answer to CST regeneration in vivo?In the early 1990s, a monoclonal anti-
body, termed IN-1, was believed to be
the solution to axonal regeneration in
the adult mammalian spinal cord (Caroni
and Schwab, 1988). At the time, the
precise identity of the IN-1 antigen was
unknown; however, it was known to be
a component of the myelin membrane,
thought to be one of the major obstacles
to spontaneous axonal regeneration after
injury. In culture the IN-1 antibody
allowed neurons to extend long pro-
cesses; when grown in the inhibitory en-
vironment of myelin and in vivo, it pro-
moted axonal regeneration (Caroni and
Schwab, 1988; Schnell and Schwab,
1990). The next steps, then, appeared
simple—identify the IN-1 antigen and its
receptor, and the molecular lock to pro-
moting spinal axon regeneration would
be opened.
Alas, as with most biological problems,
the answer was not so simple. Even be-
fore the IN-1 antigen had been cloned, an-740 Neuron 60, December 11, 2008 ª2008 Eother potent regeneration inhibitor was
identified in myelin, the myelin-associ-
ated glycoprotein (MAG) (McKerracher
et al., 1994; Mukhopadhyay et al.,
1994). The subsequent identification of
the IN-1 antigen (which may be one of
many, but the only one identified to
date) as a protein termed NogoA, re-
vealed that the protein carried two inhib-
itory domains, only one of which, within
the amino terminus, termed Amino-
Nogo, was recognized by the IN-1
antibody; the second inhibitory domain,
carried by a string of 66 amino acids,
was termed Nogo66 (GrandPre et al.,
2000; Huber and Schwab, 2000; Prinjha
et al., 2000). Later, a third myelin protein,
the oligodendrocyte-myelin glycoprotein
(OMgp) was also shown to be inhibitory
for neurite outgrowth (Wang et al.,
2002). So now there were four inhibitors
(two on NogoA) identified in myelin. As
these inhibitors shared no sequence or
even domain similarity with each other,lsevier Inc.it was presumed they would each have
their own receptor. It came as a real sur-
prise, then, that the binding partner iden-
tified for Nogo66, termed Nogo receptor
(NgR), was also shown to bind MAG
and OMgp (Domeniconi et al., 2002;
Fournier et al., 2001; Wang et al., 2002).
So, again, a somewhat simple answer
to axonal regeneration in vivo presented
itself; namely, if this single receptor could
be neutralized or eliminated in vivo, then
the effects of three of the four major in-
hibitors in myelin would be lost, and re-
generation should proceed.
Not so. Two groups reported studies in
which NgR had been knocked out. One
study, from the Strittmatter group, re-
ported a loss of the growth cone collapse
response to the myelin inhibitors and lim-
ited regeneration of the raphespinal and
rubrospinal tracts, but no regeneration
of the corticospinal tract (CST) (Kim
et al., 2004; Zheng et al., 2005). A sec-
ond study, by the Tessier-Lavigne group,
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neurite outgrowth by myelin inhibitors of
neurons from NgR null mice and wild-
type mice, and again no regeneration of
the CST (Zheng et al., 2005). The obser-
vation that neurons from the NgR null
mice were still inhibited by Nogo66
strongly suggested that there was an-
other receptor, at least for Nogo66. In
a recent paper published in Science,
a second receptor, which bound not
only Nogo66 but also MAG and OMgp
and which was capable of exerting inhi-
bition of neurite outgrowth, was de-
scribed (Atwal et al., 2008). The receptor,
first described on cells of the immune
system, and more recently shown to be
also in the nervous system (Syken
et al., 2006), is paired immunoglobulin-
like receptor B (PirB).
Based on their results with the NgR
null mice (Zheng et al., 2005), in their
quest for a second Nogo66 receptor, the
Tessier-Lavigne group screened a human
cDNA expression library for Nogo66
binding partners. They identified two
such partners—again, NgR and human
leukocyte immunoglobulin (Ig)-like recep-
tor B2 (LILRB2), which, in humans, is one
of five highly homologous family members
of B-type LILR, which contain six Ig-like
domains in their extracellular segments.
There is only one mouse ortholog of hu-
man LILRB2, PirB, and although it con-
tains four rather than six Ig-like domains
and bears only 50% homology with
the human, PirB binds not only Nogo66
but also MAG and OMgp, with, at least
for MAG, the same affinity as binding
to the NgR. To demonstrate that there
was some functional relevance to
this binding, the authors generated
a high-affinity monoclonal antibody to
PirB. They showed that this PirB antibody
was able to partially block the inhibition
by Nogo66 and total myelin of cerebellar
neurons, as well as inhibition by all
three inhibitors for dorsal root ganglion
neurons. Similar effects on partial block
of inhibition were observed when neurons
from a PirB mutant mouse were used. To
assess if blocking both PirB and NgR
resulted in a greater block of inhibition,
neurons from NgR null mice were used
together with the PirB blocking antibody.
As they reported previously (Zheng
et al., 2005), cerebellar neurons from the
NgR null mouse were inhibited as effec-tively by Nogo66 as cerebellar neurons
from wild-type mice. They now also
showed that for NgR null neurons the
PirB antibody partially, but only partially,
blocked inhibition by Nogo66, strongly
suggesting that there is yet another
Nogo66 receptor. Curiously, the same
combination—NgR null cerebellar neu-
rons and PirB antibody—was able to
completely overcome inhibition by total
myelin. This implies either that interaction
of Nogo66 with its putative third receptor
plays no role in inhibition by total myelin,
as this interaction should be unaffected
by the PirB antibody and by the absence
of the NgR, or that Nogo66 plays little or
no role in inhibition of neurite outgrowth
from cerebellar neurons by total mye-
lin—a conclusion difficult to reconcile
with the strong inhibition by Nogo66
when presented to cerebellar neurons
alone and its reported abundance in mye-
lin (GrandPre et al., 2000). It would have
been interesting to see these combination
NgR null/PirB antibody experiments car-
ried out with MAG and OMgp alone.
Would the results be like those with
Nogo66 or would their inhibition be
blocked completely when NgR and PirB
are blocked? The latter outcome would
be the prediction from the studies with to-
tal myelin, but if the former was the out-
come, then it raises the question of
whether inhibition by purified myelin is
truly the sum of the individual inhibitors.
However, from the studies described in
Atwal et al. (2008), the NgR and PirB re-
ceptors appear to be responsible for
transducing all the inhibitory signals ex-
erted by total myelin.
What is particularly interesting is that it
was previously reported that in the PirB
mutants the critical period during which
experience-driven plasticity of ocular
dominance can occur during development
is extended (Syken et al., 2006), and a sim-
ilar effect had also been reported in NgR
null mice (McGee et al., 2005). In the study
with the NgR null mice, a clear correlation
with the progress of myelination and clo-
sure of the critical period in wild-type
mice was described. From the time when
myelin was first described as being inhibi-
tory for process outgrowth, the question
has been why this alternative function for
this insulating membrane evolved. Is there
a developmental, physiological relevance
to having inhibitors of axonal growthNeuron 60, Din myelin? Now, with two studies demon-
strating extension of the critical period in
the absence of either myelin-inhibitor
receptor, the answer seems to be yes. In-
hibitors in myelin, acting through either
NgR or PirB, terminate plasticity, most
likely by limiting sprouting. The question
remains, however, why the absence of
either NgR or PirB is sufficient to extend
the critical period but both must be
blocked to overcome inhibition by myelin
in culture.
The identification of PirB as another re-
ceptor for three major myelin inhibitors of
regeneration expands our understanding
but adds to the complexity of what
prevents axonal regeneration after injury
to the brain and spinal cord. This in turn
adds PirB to the possible targets for
therapeutic intervention to promote re-
generation in vivo. There are, of course,
many questions still to be answered—
for example, is PirB part of a receptor
complex, or does it act alone? How
does it signal, and does the signaling
converge on the Rho pathway known to
be activated via NgR signaling? Does
myelination terminate other forms of de-
velopmental plasticity? The biggest
question of all, however, is whether
extensive regeneration of the CST will
occur in a NgR-PirB double knockout—
the holy grail for axonal regeneration
in vivo.
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